Scholarlink

Rationale and objectives <p>Overdose fatalities involving cocaine continue to rise with over 5.3 million cocaine users reported in the United States in 2022. The abuse liability of cocaine is reliant upon inhibition of dopamine (<b>DA</b>) reuptake and consequent increase in DA efflux in meso-corticolimbic circuitry that controls reward and motivation. Cocaine also increases serotonin (<b>5-HT</b>) efflux which is integral in cocaine abuse. The 5-HT<sub>2A</sub> receptor (<b>5-HT</b><sub><b>2A</b></sub><b>R</b>) is a key regulator of meso-corticolimbic DA release and controls cellular mechanisms underlying cocaine effects. 5-HT<sub>2A</sub>R actions contribute importantly to psychedelic mechanisms of action, and the efficacy of these compounds in limiting cocaine intake is unknown. The present studies evaluated the efficacy of acute administration of a psychedelic to reduce cocaine intake using standard and advanced preclinical models of drug self-administration.</p> Methods <p>Both a standard fixed ratio (<b>FR</b>) schedule and behavioral economics threshold procedure of cocaine intravenous self-administration were employed to evaluate the efficacy of the psychedelic 5-HT<sub>2A</sub>R agonist (−)-2,5-dimethoxy-4-iodoamphetamine [<b>(</b><b>−</b><b>)-DOI</b>] to decrease cocaine intake and motivation for cocaine in male rats. The 5-HT<sub>2A</sub>R-selective antagonist M100907 was utilized to explore the role of 5-HT<sub>2A</sub>R in the effects of (−)-DOI on cocaine intake.</p> Results <p>We found that (−)-DOI dose-dependently reduced intake on the FR5 schedule of cocaine IVSA and left shifted the demand curve to evoke greater sensitivity to price increases in the behavioral economics paradigm. Pretreatment with M100907 abated the efficacy of (−)-DOI on cocaine intake in both paradigms.</p> Conclusion <p>(−)-DOI ‘devalued’ cocaine reward and motivation to take cocaine in a 5-HT<sub>2A</sub>R-dependent manner. As serotonergic psychedelics emerge as therapeutic candidates, investigations of 5-HT<sub>2A</sub>R-acting psychedelics in preclinical analyses of cocaine intake and relapse vulnerability during abstinence will be valuable as prelude to future clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The psychedelic (−)-2,5-dimethoxy-4-iodoamphetamine [(−)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月4日

查看全文
  • Leah M. Salinsky,
  • Christina R. Merritt,
  • Erik J. Garcia,
  • Robert G. Fox,
  • Joshua C. Zamora,
  • Noelle C. Anastasio,
  • Kathryn A. Cunningham

摘要

Rationale and objectives

Overdose fatalities involving cocaine continue to rise with over 5.3 million cocaine users reported in the United States in 2022. The abuse liability of cocaine is reliant upon inhibition of dopamine (DA) reuptake and consequent increase in DA efflux in meso-corticolimbic circuitry that controls reward and motivation. Cocaine also increases serotonin (5-HT) efflux which is integral in cocaine abuse. The 5-HT2A receptor (5-HT2AR) is a key regulator of meso-corticolimbic DA release and controls cellular mechanisms underlying cocaine effects. 5-HT2AR actions contribute importantly to psychedelic mechanisms of action, and the efficacy of these compounds in limiting cocaine intake is unknown. The present studies evaluated the efficacy of acute administration of a psychedelic to reduce cocaine intake using standard and advanced preclinical models of drug self-administration.

Methods

Both a standard fixed ratio (FR) schedule and behavioral economics threshold procedure of cocaine intravenous self-administration were employed to evaluate the efficacy of the psychedelic 5-HT2AR agonist (−)-2,5-dimethoxy-4-iodoamphetamine [(−)-DOI] to decrease cocaine intake and motivation for cocaine in male rats. The 5-HT2AR-selective antagonist M100907 was utilized to explore the role of 5-HT2AR in the effects of (−)-DOI on cocaine intake.

Results

We found that (−)-DOI dose-dependently reduced intake on the FR5 schedule of cocaine IVSA and left shifted the demand curve to evoke greater sensitivity to price increases in the behavioral economics paradigm. Pretreatment with M100907 abated the efficacy of (−)-DOI on cocaine intake in both paradigms.

Conclusion

(−)-DOI ‘devalued’ cocaine reward and motivation to take cocaine in a 5-HT2AR-dependent manner. As serotonergic psychedelics emerge as therapeutic candidates, investigations of 5-HT2AR-acting psychedelics in preclinical analyses of cocaine intake and relapse vulnerability during abstinence will be valuable as prelude to future clinical trials.